Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: Results of a multicentre trial

European Journal of Clinical Investigation

Volumn 33, Issue 3, 2003, Pages 244-248

  Vernia, P ^a   Annese, V ^j   Bresci, G ^b   D'Albasio, G ^c   D'Inca R ^d   Giaccari, S ^e   Ingrosso, M ^f   Mansi, C ^g   Riegler, G ^h   Valpiani, D ⁱ   Caprilli, R ^a   Marcheggiano, A ^j   Iannoni, C ^j   Sturniolo, G C ^j   D'Imperio, N ^j   Caserta, L ^j  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e Ospedale di Galatina LE   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁱ MORGAGNI PIERANTONI HOSPITAL   (Italy)

^j Univ di Roma 'la Sapienza' ^*

more..

Author keywords

Butyrate; Clinical trial; Inflammatory bowel disease; Refractory ulcerative colitis

Indexed keywords

BUTYRIC ACID; MESALAZINE; SODIUM CHLORIDE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HISTOLOGY; HUMAN; INTESTINE MOTILITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SELF EVALUATION; SIGMOIDOSCOPY; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; BUTYRATES; CHRONIC DISEASE; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED;

EID: 12444332013     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01130.x     Document Type: Article

References (28)

1. Folwaczny C, Wiebecke B, Loeschke K. Unfractioned heparin in the therapy of patients with highly inflammatory bowel disease. Am J Gastroenterol 1999;94:1551-5.
2. Torkvist L, Thorlacius H, Sjoqvist U et al. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther 1999;13:1323-8.
3. Breuer RI, Buto SK, Christ ML et al. Rectal irrigation with short-chain fatty acids for distal UC. preliminary report. Dig Dis Sci 1991;36:185-7.
4. Vernia P, Cittadini M, Caprilli R, Torsoli A. Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate. Dig Dis Sci 1995;40:305-7.
5. Bjorck S, Dahlstrom A, Ahlman H. Topical treatment of ulcerative proctitis with lidocaine. Scand J Gastroenterol 1989;24:1061-72.
6. Salim AS. Role of oxygen-derived free radical scavengers in the management of recurrent attacks of ulcerative colitis: a new approach. J Lab Clin Med 1992;119:710-7.
7. Bregenzer N, Caesar I, Andus T, Hamling J, Malchow H, Schreiber S et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. The factor XIII Study Group. Z Gastroenterol 1999;37:999-1004.
8. Loftus EV, Tremaine WI, Nelson RA, Shoemaker JD, Sandborn JW, Phillips SF et al. Dexpanthenol enemas in ulcerative colitis: a pilot study. Mayo Clin Proc 1997;72:616-20.
9. Sandborn J, Tremaine WJ, Leighton AJ, Lawson GM, Zins BJ, Compton RF. Nicotine tartarate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment Pharmacol Ther 1997;11:663-71.
10. Griffin MG, Miner PB. Review article: refractory distal colitis - explanations and options. Aliment Pharmacol Ther 1996;10:39-48.
11. Mulder CJJ. Optimizing strategies in refractory ulcerative colitis. Ital J Gastroenterol Hepatol 1998;30:258-9.
12. D'Arienzo A, Manguso F, Castiglione GM et al. Beclomethasone dipropionate (3mg) enemas combined with oral 5-ASA (2-4 g) in the treatment of ulcerative colitis not responsive to oral 5-ASA alone. Ital J Gastroenterol Hepatol 1998;30:254-7.
13. Truelove CD, Witts LJ. Cortisone in ulcerative colitis. Br Med J 1955;ii:1041-8.
14. Sutherland LR, Martin F, Greer S et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92:1894-8.
15. Scheppach W, Sommer H, Kirchner T et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 1992;103:51-6.
16. Steinhart AH, Brzezinski A, Baker JP. Treatment of refractor ulcerative proctosigmoiditis with butyrate enemas. Am J Gastroenterol 1994;89:179-83.
17. Patz J, Jacobsohn WZ, Gottschalk-Sabag S et al. Treatment of refractory distal ulcerative colitis with short-chain fatty acid enemas. Am J Gastroenterol 1996;91:731-4.
18. Kim YI. Short chain fatty acids in ulcerative colitis. Nutr Rev 1998;56:17-24.
19. Ilnyckyj A, Shanahan F, Anton AP, Cheang M, Bernstein NC. Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997;112:1854-8.
20. Roediger WEW. The colonic epithelium in ulcerative colitis: an energy deficiency disease. Lancet 1980;2:712-5.
21. Allan ES, Winter S, Light AM, Allan A. Mucosal enzyme activity for butyrate oxidation: no defect in patients with ulcerative colitis. Gut 1996;38:886-93.
22. Jørgensen J, Mortensen PB. Substrate utilization by intestinal mucosal tissue strips from patients with inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2001;281:G405-11.
23. Liu Q, Shimoyama T, Suzuki K et al. Effect of sodium butyrate on reactive oxygen species generation by human neutrophils. Scand J Gastroenterol 2001;36:744-50.
24. Segain JP, Raingeard de la Blétiere D, Bourreille A et al. Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease. Gut 1989;47:397-403.
25. Kripke SA, Fox AD, Berman JM, Settle RG, Rombeau JL. Stimulation of intestinal mucosal growth with intracolonic infusion of SCFA. JPEN 1989;13:109-16.
26. Velazquez OC, Lederer HM, Rombeau JKL. Butyrate and the coloncyte: implications for neoplasia. Dig Dis Sci 1996;41:727-39.
27. Sobajima J, Ozaki S, Okazaki T, Osakada F, Sumita S, Mori K et al. Anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis: anti-cathepsin G and a novel antibody correlated with refractory type. Clin Exp Immunol 1996;105:120-4.
28. Hearing SD, Norman M, Probert CS, Haslam N, Dayan CM. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 1999;45:382-8.